Clinical utility of serum holotranscobalamin as a marker of cobalamin status in elderly patients with neuropsychiatric symptoms
-
Karin Nilsson
Abstract
Early diagnosis of cobalamin deficiency is crucial, owing to the latent nature of this disorder and the resulting possible irreversible neurological damage. A normal serum cobalamin concentration does not reliably rule out a functional cobalamin deficiency and there does not at present seem to be any single diagnostic approach to achieve this diagnosis. A new marker for cobalamin status is the serum concentration of cobalamin bound to transcobalamin II (holoTC). Because methods suitable for routine use have been unavailable until recently, the clinical value of lowholoTC is still uncertain. Furthermore, there is at the moment no gold standard or true reference method to diagnose subtle cobalamin deficiency, which makes evaluation of the clinical usefulness of holoTC and the estimation of sensitivity and specificity problematic. In this study, we aimed to assess whether low holoTC concentrations are congruent with other biochemical signs of cobalamin deficiency in a group of psychogeriatric patients. The findings in the present study showthat holoTC is strongly related to serum cobalamin (0.68; p<0.001 in both patients and controls). Distribution of the different markers for cobalamin/folate status in the 33 patients with low levels of serum holoTC (below40 pmol/l) showed that 17 patients had normal levels of the other markers for cobalamin status. This may indicate poor specificity of lowholoTC for cobalamin deficiency. In 23 out of 176 patients with normal levels of holoTC we observed pathological levels of other markers for cobalamin deficiency. The use of holoTC in the present study group did not give significant additional information other than that given by serum cobalamin and therefore cannot be recommended in this clinical setting.
Copyright © 2004 by Walter de Gruyter GmbH & Co. KG
Articles in the same Issue
- Publishers note
- Towards quality specifications in extra-analytical phases of laboratory activity
- Quality indicators and specifications for the extra-analytical phases in clinical laboratory management
- Pitfalls and drawbacks in screening of congenital disorders of glycosylation
- Activity of eosinophils and immunoglobulin E concentration in the peritoneal fluid of women with endometriosis
- Rapid generation of detailed loss of heterozygosity profiles for routine diagnosis of gliomas
- Presence of secretory group IIa and V phospholipase A2 and cytosolic group IVα phospholipase A2 in chondrocytes from patients with rheumatoid arthritis
- Neurokinin B levels in maternal circulation during early pregnancy
- Cl- regulates cryoglobulin structure: a new hypothesis for the physiopathological mechanism of temperature non-dependent cryoprecipitation
- Urine labeling with orally applied marker substances in drug substitution therapy
- Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure
- Clinical utility of serum holotranscobalamin as a marker of cobalamin status in elderly patients with neuropsychiatric symptoms
- Comparison of serum creatinine, uric acid, albumin and glucose in male professional endurance athletes compared with healthy controls
- Low S-adenosylmethionine concentrations found in patients with severe inflammatory bowel disease
- Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3)
- The influence of freezer storage of urine samples on the BONN-Risk-Index for calcium oxalate crystallization
- First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay – Lp(a) SRM 2B
- Myeloma cells produce sialyl salivary-type amylase
- Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors
- Meetings and Awards
Articles in the same Issue
- Publishers note
- Towards quality specifications in extra-analytical phases of laboratory activity
- Quality indicators and specifications for the extra-analytical phases in clinical laboratory management
- Pitfalls and drawbacks in screening of congenital disorders of glycosylation
- Activity of eosinophils and immunoglobulin E concentration in the peritoneal fluid of women with endometriosis
- Rapid generation of detailed loss of heterozygosity profiles for routine diagnosis of gliomas
- Presence of secretory group IIa and V phospholipase A2 and cytosolic group IVα phospholipase A2 in chondrocytes from patients with rheumatoid arthritis
- Neurokinin B levels in maternal circulation during early pregnancy
- Cl- regulates cryoglobulin structure: a new hypothesis for the physiopathological mechanism of temperature non-dependent cryoprecipitation
- Urine labeling with orally applied marker substances in drug substitution therapy
- Cardiac natriuretic hormones, neuro-hormones, thyroid hormones and cytokines in normal subjects and patients with heart failure
- Clinical utility of serum holotranscobalamin as a marker of cobalamin status in elderly patients with neuropsychiatric symptoms
- Comparison of serum creatinine, uric acid, albumin and glucose in male professional endurance athletes compared with healthy controls
- Low S-adenosylmethionine concentrations found in patients with severe inflammatory bowel disease
- Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3)
- The influence of freezer storage of urine samples on the BONN-Risk-Index for calcium oxalate crystallization
- First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay – Lp(a) SRM 2B
- Myeloma cells produce sialyl salivary-type amylase
- Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors
- Meetings and Awards
